scholarly journals Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.

1996 ◽  
Vol 97 (3) ◽  
pp. 728-735 ◽  
Author(s):  
M A Friedlander ◽  
Y C Wu ◽  
A Elgawish ◽  
V M Monnier
Keyword(s):  
Peritoneal Dialysis ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Kinetics Of Formation ◽  
Kinetics Of ◽  
Advanced Glycosylation

Peritoneal Accumulation of Advanced Glycosylation End-Products in Diabetic Rats on Dialysis with Icodextrin

2000 ◽  
Vol 20 (5_suppl) ◽  
pp. 39-47 ◽  
Author(s):  
Jeong Ho Lee ◽  
Dheerendra K. Reddy ◽  
Rajiv Saran ◽  
Harold L. Moore ◽  
Zbylut J. Twardowski ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Glucose Solution ◽  
Diabetic Rats ◽  
Diabetic Rat ◽  
Peritoneal Membrane ◽  
Sprague Dawley ◽  
Advanced Glycosylation End Products ◽  
Group I ◽  
End Products ◽  
Advanced Glycosylation

Objective To evaluate and compare the effects of glucose-based solutions to those of icodextrin with respect to peritoneal transport characteristics and formation of advanced glycosylation end-products (AGEs) in the peritoneal membrane in the diabetic rat model of peritoneal dialysis (PD). Study Design Thirty-three male Sprague–Dawley rats weighing between 275 – 300 g were divided into 5 groups: group C ( n = 6), control rats with catheter but not dialyzed; group D ( n = 5), diabetic rats with catheter but not dialyzed; group G ( n = 7), diabetic rats dialyzed with standard 2.5% glucose solution for daytime exchanges and 4.25% glucose solution for the overnight exchange; group H ( n = 8), diabetic rats dialyzed with standard 2.5% glucose solution for daytime exchanges and 7.5% icodextrin solution for overnight exchanges; group I ( n = 7), diabetic rats dialyzed with 7.5% icodextrin solution for all exchanges. Dialysis exchanges were performed three times daily with an instillation volume of 25 mL per exchange for a period of 12 weeks. Tissue sections were stained using a monoclonal anti-AGE antibody. One-hour peritoneal equilibration tests (PET) were performed every 4 weeks for comparison of transport characteristics. Results The level of immunostaining was lowest in group C and highest in group G. Significant differences were seen between group C and groups G, H, and I ( p < 0.001, p = 0.001, and p < 0.05 respectively). Significant differences were also found between group G and groups D and I ( p < 0.05 and p < 0.05 respectively). Over time, glucose concentration at the end of an exchange versus concentration at instillation (D/D0 glucose) decreased and dialysate-to-plasma ratio (D/P) of urea increased. Significant differences were found between groups C and H for D/D0 glucose (0.40 ± 0.01 vs 0.35 ± 0.01, p < 0.05); and between groups C and H for D/P urea (0.87 ± 0.03 vs 0.97 ± 0.02, p < 0.05). Conclusions These results suggest that AGE formation is lower with the use of peritoneal dialysis solution containing icodextrin than with glucose-based solutions. We conclude that the use of icodextrin may be helpful in slowing the deterioration of the peritoneal membrane, prolonging its use for dialysis.

Serum Advanced Glycosylation End-Products in Patients on Hemodialysis and CAPD

1995 ◽  
Vol 15 (2) ◽  
pp. 129-133 ◽  
Author(s):  
Arasb Ateshkadi ◽  
Curtis A. Johnson ◽  
Henry W. Founds ◽  
Stephen W. Zimmerman
Keyword(s):  
Clinical Trial ◽  
Peritoneal Dialysis ◽  
Hemoglobin A1c ◽  
Hemodialysis Patients ◽  
Blood Samples ◽  
Advanced Glycosylation End Products ◽  
Peptide Concentration ◽  
End Products ◽  
The Mean ◽  
Advanced Glycosylation

Objectives Part I: To evaluate the long-term effects of daily glucose absorption from the peritoneal dialysis fluid on the formation of low-molecular-weight advanced glycosylation end products (AGE-peptides) in nondiabetic continuous ambulatory peritoneal dialysis (CAPD) patients. Part II: To determine the acute effect of CAPD on serum AGE-peptide concentrations. Design Part I: Noninterventional, parallel, cross-sectional clinical trial. Part II: Crossover clinical trial. Setting A university-based hospital, and clinics. Patients Part I: Sixty nondiabetic subjects recruited into three age-matched (:1:5 years) groups, as follows: 20 healthy volunteers (controls); 20 hemodialysis patients; and 20 CAPD patients. Part II: Eight patients with diabetes mellitus (type lor II) and chronic renal failure who were about to undergo CAPD. Intervention Part I: None. Part II: Uninterrupted CAPD, as medically required. Measurements Part I: To determine serum AGEpeptide concentrations blood samples were obtained randomly from controls and CAPD patients, and predialysis from hemodialysis patients. Hemoglobin A1c was also measured in all subjects. Part II: To determine serum AGE-peptide concentrations, blood samples were collected within one month prior to initiation of CAPD (predialysis) and, again, one week after initiation of uninterrupted CAPD (postdialysis). Hemoglobin A1c was measured predialysis. Results Part I: Mean hemoglobin A1c values for all groups were within the normal range; however, the mean value for CAPD patients was significantly higher than for both hemodialysis patients and healthy controls (controls, 5.21%:1:0.6%; hemodialysis, 5.12%:1:0.5%; CAPD, 5.78%:1:0.6%; p < 0.01). The dialysis patients had a significantly higher mean serum AGE-peptide concentration than the control subjects (controls, 7.02:1:3.4 units/mL; hemodialysis, 11.9:1:3.6 units/mL; CAPD, 11.1:1:4.5 units/mL; p < 0.01). There was no difference in the mean serum AGE-peptide concentration of patients in the hemodialysis and CAPD groups. Part II: The mean hemoglobin A1c value in the diabetic predialysis patients was 9.2%:1:1.9%. There was no difference between the predialysis and postdialysis serum AGE-peptide concentrations (predialysis, 16.9:1:9.6 units/mL; postdialysis, 16.0:1:2.9 units/mL; p = 0.78). Conclusions Despite the increased glucose load and the higher hemoglobin A1c values, indicating poor glycemic control, nondiabetic CAPD patients did not have higher serum AGEpeptide concentrations than the nondiabetic hemodialysis patients. In diabetic patients, CAPD did not further increase the serum concentrations of AGEpeptides.

scholarly journals Influences of advanced glycosylation end products on the inner blood–retinal barrier in a co-culture cell model in vitro

2020 ◽  
Vol 15 (1) ◽  
pp. 619-628
Author(s):  
Chen Yuan ◽  
Ya Mo ◽  
Jie Yang ◽  
Mei Zhang ◽  
Xuejun Xie
Keyword(s):  
Electrical Resistance ◽  
Cell Model ◽  
Polyclonal Antibodies ◽  
Time Dependent ◽  
Dependent Manner ◽  
Blood Retinal Barrier ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Advanced Glycosylation

AbstractAdvanced glycosylation end products (AGEs) are harmful factors that can damage the inner blood–retinal barrier (iBRB). Rat retinal microvascular endothelial cells (RMECs) were isolated and cultured, and identified by anti-CD31 and von Willebrand factor polyclonal antibodies. Similarly, rat retinal Müller glial cells (RMGCs) were identified by H&E staining and with antibodies of glial fibrillary acidic protein and glutamine synthetase. The transepithelial electrical resistance (TEER) value was measured with a Millicell electrical resistance system to observe the leakage of the barrier. Transwell cell plates for co-culturing RMECs with RMGCs were used to construct an iBRB model, which was then tested with the addition of AGEs at final concentrations of 50 and 100 mg/L for 24, 48, and 72 h. AGEs in the in vitro iBRB model constructed by RMEC and RMGC co-culture led to the imbalance of the vascular endothelial growth factor (VEGF) and pigment epithelial derivative factor (PEDF), and the permeability of the RMEC layer increased because the TEER decreased in a dose- and time-dependent manner. AGEs increased VEGF but lowered PEDF in a dose- and time-dependent manner. The intervention with AGEs led to the change of the transendothelial resistance of the RMEC layer likely caused by the increased ratio of VEGF/PEDF.

Advanced Glycosylation End Products in Patients with Diabetic Nephropathy

1991 ◽  
Vol 325 (12) ◽  
pp. 836-842 ◽  
Author(s):  
Zenji Makita ◽  
Steven Radoff ◽  
Elliot J. Rayfield ◽  
Zhi Yang ◽  
Edward Skolnik ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Advanced Glycosylation

scholarly journals PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products

1995 ◽  
Vol 48 (1) ◽  
pp. 111-117 ◽  
Author(s):  
Douglas C. Throckmorton ◽  
Anne P. Brogden ◽  
Brian Min ◽  
Howard Rasmussen ◽  
Michael Kashgarian
Keyword(s):  
Mesangial Cells ◽  
Collagen Production ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Advanced Glycosylation

Advanced Glycosylation End Products and Trans Fatty Acids Measured in Typical and Greater Consumption Food in Mexico.

2010 ◽  
pp. P2-575-P2-575
Author(s):  
CV Quintanilla-Garcia ◽  
ME Garay-Sevilla ◽  
G Barbosa-Sabanero ◽  
K Wrobel-Zasada ◽  
C Rodriguez-Flores ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Trans Fatty Acids ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Advanced Glycosylation
Sign in / Sign up

Export Citation Format

Share Document